Cargando…

ARID1A deficiency associated with MMR deficiency and a high abundance of tumor-infiltrating lymphocytes predicts a good prognosis of endometrial carcinoma

BACKGROUND: ARID1A alterations have been detected in 40% of endometrial carcinomas (ECs) and are associated with loss of its expression. The role of ARID1A in tumorigenesis and development is complex, and the prognostic role in EC remains controversial. Hence, it is of great significance to confirm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Dantong, Zhao, Han, Zhou, Hai, Tao, Junyan, Li, Tianjun, Zhu, Jingjuan, Hou, Helei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176062/ https://www.ncbi.nlm.nih.gov/pubmed/37137217 http://dx.doi.org/10.1016/j.tranon.2023.101685

Ejemplares similares

Case Report: Life-threatening hypercalcemia associated with MMR-deficient endometrial carcinoma secreting parathyroid hormone
por: Liu, Huazhen, et al.
Publicado: (2023)

MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
por: Fraune, Christoph, et al.
Publicado: (2020)

ARID1A‐deficient cells require HDAC6 for progression of endometrial carcinoma
por: Megino‐Luque, Cristina, et al.
Publicado: (2022)

MMR-deficiency and BRCA2/EGFR/NTRK mutations
por: Gokare, Prashanth, et al.
Publicado: (2017)

Correction to: MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes
por: Fraune, Christoph, et al.
Publicado: (2022)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
por: Sun, Dantong, et al.
Publicado: (2020)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
por: Tao, Junyan, et al.
Publicado: (2020)

A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report
por: Cui, Jiantao, et al.
Publicado: (2023)

Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
por: Lin, Andy Yingjie, et al.
Publicado: (2015)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Tumor-Infiltrating CD8-Positive T-Cells Associated with MMR and p53 Protein Expression Can Stratify Endometrial Carcinoma for Prognosis
por: Munakata, Satoru, et al.
Publicado: (2023)

Endometrial cancer risk and survival by tumor MMR status
por: Nagle, Christina M., et al.
Publicado: (2018)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
por: Sun, Dantong, et al.
Publicado: (2020)

MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Histone Proteomic Networks
por: Hacking, Sean, et al.
Publicado: (2023)

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
por: Zheng, Guoxing, et al.
Publicado: (2023)

High Tumor Infiltrating Lymphocytes Are Associated with Overall Survival and Good Prognostic Parameters in Endometrial Endometrioid Carcinoma Patients
por: Ozturk, Cigdem, et al.
Publicado: (2023)

Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report
por: Valls, Maia L., et al.
Publicado: (2022)

Heterogeneity in the lymphocytic infiltration of deficient DNA mismatch repair colon cancers
por: Yoon, Harry H., et al.
Publicado: (2018)

Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas
por: Fraune, Christoph, et al.
Publicado: (2020)

The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas
por: Guo, Yu-e, et al.
Publicado: (2022)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Deep Learning Applied to Raman Spectroscopy for the Detection of Microsatellite Instability/MMR Deficient Colorectal Cancer
por: Blake, Nathan, et al.
Publicado: (2023)

Targeting HSPA1A in ARID2-deficient lung adenocarcinoma
por: Wang, Xue, et al.
Publicado: (2021)

Targeting the Metabolic Vulnerability of ARID1A-Deficient Hepatocellular Carcinoma
por: Chan, For-Fan, et al.
Publicado: (2022)

Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective
por: Lebedev, Timofey, et al.
Publicado: (2023)

Deficiencies and How They Will Be Made Good
Publicado: (1913)

Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency
por: Sun, Dantong, et al.
Publicado: (2023)

Disappearance of MMR-deficient subclones after controlled IL-12 and PD-1 inhibition in a glioma patient
por: McCord, Matthew, et al.
Publicado: (2021)

Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters
por: Hashmi, Atif A, et al.
Publicado: (2023)

MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation
por: Patel, Rutulkumar, et al.
Publicado: (2018)

Advancement in research and therapy of NF1 mutant malignant tumors
por: Tao, Junyan, et al.
Publicado: (2020)

Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer
por: Vietri, Maria Teresa, et al.
Publicado: (2021)

The role of CD28 in the prognosis of young lung adenocarcinoma patients
por: Sun, Dantong, et al.
Publicado: (2020)

Efficacy of PD-1 Inhibitor Combined with Bevacizumab in Treatment of Advanced Endometrial Cancer Patients with Mismatch Repair Deficiency (dMMR)/High-Level Microsatellite Instability (MSI-H)
por: Liao, Ying, et al.
Publicado: (2022)

DNA repair deficiency in peripheral blood lymphocytes of endometrial cancer patients with a family history of cancer
por: Buchynska, Lyubov, et al.
Publicado: (2014)

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
por: Takahashi, Kazuaki, et al.
Publicado: (2021)

Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
por: Song, Yunfeng, et al.
Publicado: (2021)

Relevance of ARID1A Mutations in Endometrial Carcinomas
por: De Leo, Antonio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_orvr17vr4v9e1bi83fjgt4uhlt